Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
LIM and SH3 protein 1
(
LASP-1
) plays a significant role in the formation of several malignant tumours. However, the biological and clinical significances of
LASP-1
in hepatocellular carcinoma (HCC) remain largely unknown. Using immunohistochemistry, we analysed
LASP-1
expression in 144 clinicopathologically characterised HCC cases. Using gene and transfection and RNA interference, we investigated the effects of
LASP-1
overexpression and depletion on tumour cellular behaviour in vitro.
LASP-1
expression was detected in not only cytoplasm and but also nucleus of HCC and liver cells. The positive rates of both cytosolic and nuclear
LASP-1
expression in HCC were higher than adjacent non-tumourous tissues. Statistical analysis showed that heterogeneous
LASP-1
expression is associated with
hepatitis B
surface antigen (HBsAg) and serum alpha-fetoprotein (AFP) level of HCC patients. A significant trend was identified between cytosolic
LASP-1
overexpression in HCC and worsening clinical prognosis. Multivariate survival analysis showed that cytosolic
LASP-1
expression was recognised as an independent prognostic factor of patient's survival. In vitro study showed
LASP-1
promoted cell proliferation and migration, and resulted in aggressive phenotypes of cancer cells.
LASP-1
is a valuable marker of HCC progression. High cytosolic
LASP-1
expression is associated with poor overall survival in HCC patients.
...
PMID:LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. 2308 41
